Vietnam Oral Solid Dosage Contract Manufacturing Market Size and Forecast 2032

Vietnam Oral Solid Dosage Contract Manufacturing Market Overview:

The Vietnam Oral Solid Dosage Contract Manufacturing Market size was valued at USD 98 million in 2024 and is anticipated to reach USD 162.17 million by 2032, growing at a CAGR of 6.48% during the forecast period.

Vietnam Oral Solid Dosage Contract Manufacturing Market Insights

• Rising outsourcing by domestic and export-oriented pharma firms accelerates demand for high-volume tablet and capsule manufacturing, led by tablets with 46.3% segment share in 2024.
• Immediate-release formulations dominate with 52.8% share in 2024, while controlled-release at 31.2% gains momentum as manufacturers expand modified-release capabilities for chronic therapies.
• Leading players including DHG Pharma, Traphaco, Hau Giang, Imexpharm, and Pymepharco strengthen scale through GMP compliance, capacity upgrades, and cost-efficient production amid pricing pressure and higher QA requirements.
• Southern Vietnam leads with 41.2% regional share in 2024, followed by Northern Vietnam at 34.6% and Central Vietnam at 24.2%, supported by export logistics, regulatory proximity, and expanding industrial zones.

Vietnam Oral Solid Dosage Contract Manufacturing Market Segmentation Analysis:

By Type:

The Vietnam Oral Solid Dosage Contract Manufacturing Market by type is led by tablets, which accounted for 46.3% market share in 2024, driven by high prescription volumes, ease of large-scale manufacturing, and strong demand for chronic disease therapies. Tablets remain the preferred format for cardiovascular, anti-diabetic, and analgesic drugs due to dose accuracy, stability, and cost efficiency. Capsules held 28.6% share, supported by nutraceutical and specialty drug demand, while powders and granules together represented 17.4%, primarily for pediatric and geriatric formulations. Advanced coating and compression capabilities continue to reinforce tablet dominance.

• For instance, Stellapharm installed Vietnam's first contained integrated granulation line with two MODUL P rotary tablet presses at its Binh Duong facility for producing steroid/hormonal tablets used in chronic therapies.

By Mechanism:

By mechanism, immediate-release formulations dominated with a 52.8% share in 2024, supported by widespread use in acute therapies, faster regulatory approvals, and lower production complexity. Immediate-release products are extensively outsourced by domestic pharmaceutical firms to optimize cost and capacity utilization. Controlled-release formulations captured 31.2% share, driven by rising demand for sustained therapeutic effects in chronic treatments such as hypertension and diabetes. Delayed-release products accounted for 16.0%, benefiting from increasing gastrointestinal and targeted drug delivery applications. Growing investments in formulation expertise continue to support mechanism-based diversification.

• For instance, EUDRAGIT® L 30 D-55 polymers protect acid-sensitive APIs like proton pump inhibitors during gastric transit before releasing in the small intestine.

By End-user:

Based on end-user, large-size pharmaceutical companies held the dominant share of 58.7% in 2024, driven by high-volume outsourcing, strong export orientation, and compliance with international manufacturing standards. These companies leverage contract manufacturing to scale production while focusing on R&D and brand development. Medium- and small-size companies accounted for 32.9%, supported by increasing domestic drug registrations and cost-driven outsourcing strategies. The remaining 8.4% share was held by other entities, including nutraceutical and specialty healthcare firms, reflecting the expanding scope of oral solid dosage contract manufacturing services in Vietnam.

Key Growth Drivers

Rising Outsourcing by Domestic and Export-Oriented Pharmaceutical Companies

The Vietnam Oral Solid Dosage Contract Manufacturing Market is experiencing strong growth due to increasing outsourcing by both domestic and export-focused pharmaceutical companies. Rising pressure to reduce capital expenditure, optimize operational efficiency, and accelerate time-to-market is encouraging manufacturers to rely on specialized contract partners. Local pharmaceutical firms increasingly outsource tablet and capsule production to scale volumes without expanding in-house facilities. At the same time, export-oriented companies leverage Vietnamese CMOs to meet regional demand across Southeast Asia, benefiting from competitive manufacturing costs, skilled labor availability, and improving compliance with international quality standards.

• For instance, Ha Tay Pharmaceutical Joint Stock Company offers contract manufacturing services for tablets and capsules to domestic partners like Kim Long Investment Joint Stock Company and Dong Au Pharmaceutical Joint Stock Company, leveraging its PIC/S GMP-compliant facilities to enable scaled production without client facility expansions.

Expanding Chronic Disease Burden and Solid Dosage Demand

The growing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and respiratory conditions is significantly driving demand for oral solid dosage forms in Vietnam. Tablets and capsules remain the preferred formats for long-term therapies due to their stability, dosing accuracy, and patient convenience. This sustained demand is encouraging pharmaceutical companies to expand product portfolios while outsourcing manufacturing to contract partners with high-capacity compression, coating, and formulation capabilities. As chronic disease management expands across urban and aging populations, contract manufacturers are witnessing steady volume growth and longer-term supply agreements.

• For instance, STADA Pymepharco supplies generics like tablets and capsules for chronic respiratory, cardiovascular, and diabetes care through partnerships such as with Pharmacity, focusing on affordable dose-reduced combokits to boost patient compliance.

Strengthening Regulatory Framework and Manufacturing Infrastructure

Vietnam’s strengthening pharmaceutical regulatory framework is playing a critical role in market expansion by enhancing confidence in local contract manufacturing services. Continuous improvements in Good Manufacturing Practice compliance, quality control systems, and inspection transparency are enabling contract manufacturers to attract multinational and regional clients. Government support for pharmaceutical self-sufficiency and export readiness is also accelerating investments in modern production lines and analytical laboratories. These improvements reduce regulatory risks for outsourcing companies while positioning Vietnam as a reliable manufacturing hub for oral solid dosage products across Southeast Asia.

Key Trends & Opportunities

Growing Demand for Modified-Release and Value-Added Formulations

The Vietnam Oral Solid Dosage Contract Manufacturing Market is witnessing a shift toward modified-release and value-added formulations, creating new growth opportunities for contract manufacturers. Pharmaceutical companies increasingly seek partners capable of producing controlled-release, delayed-release, and multi-layer tablets to differentiate products and improve patient adherence. This trend is driven by rising chronic disease treatments and the need for extended therapeutic efficacy. Contract manufacturers investing in advanced formulation technologies, specialized excipients, and process optimization are well positioned to secure long-term partnerships and higher-margin projects within both domestic and export markets.

• For instance, Traphaco partnered with Daewoong Pharmaceutical for technology transfer of advanced dosage forms, initiating phase 2 manufacturing at its Hung Yen facility with support from four Korean experts.

Expansion of Export-Oriented Contract Manufacturing Services

Export-oriented manufacturing is emerging as a major opportunity as Vietnamese contract manufacturers expand their presence beyond domestic markets. Companies are increasingly targeting regulated and semi-regulated markets in Southeast Asia, the Middle East, and Africa by aligning production with international quality and documentation requirements. Competitive production costs, favorable trade policies, and improving regulatory recognition are enabling contract manufacturers to attract overseas pharmaceutical clients. This trend is encouraging investments in capacity expansion, serialization, and packaging upgrades, positioning Vietnam as a strategic regional hub for oral solid dosage contract manufacturing.

• For instance, RV Group acquired OPV Pharmaceuticals in Bien Hoa Industrial Estate, enhancing its general-purpose oral solid dosage capabilities for ASEAN growth. It further expanded by acquiring BRV Pharma in Cu Chi Industrial Estate, focusing on oral solid dosage, oral liquids, and oncology orals to support export strategies.

Key Challenges

Regulatory Compliance and Quality Consistency Pressure

Maintaining consistent regulatory compliance remains a key challenge for the Vietnam Oral Solid Dosage Contract Manufacturing Market. Contract manufacturers must continuously meet evolving domestic and international regulatory expectations, including documentation accuracy, validation requirements, and audit readiness. Smaller manufacturers often face challenges in upgrading facilities, training personnel, and maintaining robust quality management systems. Any lapses in compliance can impact client trust and limit access to export markets. The growing scrutiny from regulatory authorities increases operational complexity and cost, particularly for manufacturers aiming to serve multinational pharmaceutical clients.

Intense Pricing Competition and Margin Constraints

Intense pricing competition presents a significant challenge as numerous contract manufacturers compete for similar outsourcing projects. Pharmaceutical companies exert strong pricing pressure to minimize production costs, which can compress margins for contract manufacturers. Rising input costs, including raw materials, energy, and labor, further strain profitability. Smaller and mid-sized manufacturers face difficulties balancing competitive pricing with investments in technology, compliance, and capacity expansion. Sustained margin pressure may limit innovation and slow modernization efforts, impacting long-term competitiveness in the Vietnam Oral Solid Dosage Contract Manufacturing Market.

Regional Analysis

Northern Vietnam

Northern Vietnam accounted for 34.6% market share in 2024 in the Vietnam Oral Solid Dosage Contract Manufacturing Market, supported by the presence of major pharmaceutical manufacturing hubs around Hanoi and neighboring provinces. The region benefits from strong regulatory oversight, proximity to government agencies, and a high concentration of GMP-certified facilities. Contract manufacturers in Northern Vietnam actively serve domestic pharmaceutical companies and public healthcare supply chains, particularly for tablets and immediate-release formulations. Growing investments in formulation development, quality testing infrastructure, and workforce training continue to strengthen the region’s position in high-volume and compliance-driven contract manufacturing activities.

Southern Vietnam

Southern Vietnam dominated the Vietnam Oral Solid Dosage Contract Manufacturing Market with a 41.2% share in 2024, driven by its advanced industrial ecosystem and export-oriented pharmaceutical clusters in Ho Chi Minh City and surrounding provinces. The region hosts a large number of established contract manufacturers with high-capacity production lines and international quality certifications. Strong logistics connectivity, access to ports, and proximity to key pharmaceutical clients support large-scale outsourcing contracts. Southern Vietnam also leads in capsule and controlled-release manufacturing, supported by continuous investments in automation, packaging capabilities, and export-focused compliance standards.

Central Vietnam

Central Vietnam held a 24.2% market share in 2024, reflecting its growing role as an emerging manufacturing base in the Vietnam Oral Solid Dosage Contract Manufacturing Market. The region benefits from lower operating costs, expanding industrial zones, and increasing government support for pharmaceutical manufacturing decentralization. Contract manufacturers in Central Vietnam primarily serve medium- and small-size pharmaceutical companies, focusing on tablets, powders, and granules. Infrastructure development, improved transportation networks, and rising investments in GMP-compliant facilities are steadily enhancing the region’s manufacturing capabilities and its attractiveness for cost-efficient outsourcing projects.

Vietnam Oral Solid Dosage Contract Manufacturing Market Segmentations:

By Type

• Tablets
• Capsules
• Powders
• Granules
• Others (Lozenges, Gummies, Pastilles, etc.)

By Mechanism

• Immediate-release
• Delayed-release
• Controlled-release

By End-user

• Large-size Companies
• Medium- & Small-size Companies
• Others

 By Geography

• Northern Vietnam
• Southern Vietnam
• Central Vietnam

Competitive Landscape

The Vietnam Oral Solid Dosage Contract Manufacturing Market features a moderately consolidated structure, supported by the presence of established domestic pharmaceutical manufacturers with expanding contract manufacturing capabilities, including DHG Pharmaceutical Joint Stock Company, Traphaco Joint Stock Company, Hau Giang Pharmaceutical, Imexpharm Corporation, Pymepharco, OPV Pharmaceutical, Mekophar Chemical Pharmaceutical, Vietnam Pharmaceutical Corporation (Vinapharm), Vimedimex Medi-Pharma, and Everpia JSC. Market participants focus on capacity expansion, GMP compliance, and formulation expertise to strengthen outsourcing partnerships. Leading players invest in high-speed tablet compression, capsule filling, and coating technologies to support large-volume and export-oriented contracts. Strategic collaborations with regional pharmaceutical firms, investments in quality systems, and portfolio diversification across immediate- and modified-release formulations enhance competitiveness. Increasing emphasis on regulatory readiness, cost efficiency, and scalable production positions Vietnamese manufacturers as preferred partners for domestic and Southeast Asian pharmaceutical outsourcing.

Key Player Analysis

• Imexpharm Corporation
• OPV Pharmaceutical
• Everpia JSC
• Hau Giang Pharmaceutical
• Vimedimex Medi-Pharma
• Traphaco Joint Stock Company
• Pymepharco
• DHG Pharmaceutical Joint Stock Company
• Mekophar Chemical Pharmaceutical
• Vietnam Pharmaceutical Corporation (Vinapharm)

Recent Developments

• In May 2025, Imexpharm Pharmaceutical JSC announced plans to build a $58 million high-tech pharmaceutical plant in Dong Thap province, featuring EU-GMP production lines for advanced oral solid dosage forms to support contract manufacturing expansion.
• In March 2025, Davipharm outlined plans to develop 12 new SKUs annually for international markets, expanding its oral solid dosage production alongside a new warehouse and quality control lab.​

Report Coverage

The research report offers an in-depth analysis based on Type, Mechanism, End User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. The Vietnam Oral Solid Dosage Contract Manufacturing Market will continue expanding due to rising outsourcing by domestic and regional pharmaceutical companies.
2. Increasing demand for tablets and capsules used in chronic disease management will support long-term volume growth.
3. Contract manufacturers will invest in advanced formulation technologies to support controlled- and delayed-release products.
4. Strengthening regulatory compliance will improve access to regional and international export markets.
5. Capacity expansion and automation will enhance production efficiency and consistency.
6. Export-oriented manufacturing will gain traction across Southeast Asia, the Middle East, and Africa.
7. Medium- and small-size pharmaceutical companies will increasingly rely on contract partners to optimize costs.
8. Growing focus on quality assurance and documentation will strengthen client trust and long-term contracts.
9. Strategic partnerships with regional pharmaceutical firms will support portfolio diversification.
10. Continued government support for pharmaceutical manufacturing will reinforce Vietnam’s position as a regional outsourcing hub.